555 related articles for article (PubMed ID: 18559493)
1. Oncolytic vesicular stomatitis viruses are potent agents for intravesical treatment of high-risk bladder cancer.
Hadaschik BA; Zhang K; So AI; Fazli L; Jia W; Bell JC; Gleave ME; Rennie PS
Cancer Res; 2008 Jun; 68(12):4506-10. PubMed ID: 18559493
[TBL] [Abstract][Full Text] [Related]
2. Intravesical chemotherapy of high-grade bladder cancer with HTI-286, a synthetic analogue of the marine sponge product hemiasterlin.
Hadaschik BA; Adomat H; Fazli L; Fradet Y; Andersen RJ; Gleave ME; So AI
Clin Cancer Res; 2008 Mar; 14(5):1510-8. PubMed ID: 18316576
[TBL] [Abstract][Full Text] [Related]
3. Intravesically administered antisense oligonucleotides targeting heat-shock protein-27 inhibit the growth of non-muscle-invasive bladder cancer.
Hadaschik BA; Jackson J; Fazli L; Zoubeidi A; Burt HM; Gleave ME; So AI
BJU Int; 2008 Aug; 102(5):610-6. PubMed ID: 18384625
[TBL] [Abstract][Full Text] [Related]
4. [Oncolytic vesicular stomatitis viruses as intravesical agents against non-muscle-invasive bladder cancer].
Hadaschik BA; Zhang K; So AI; Bell JC; Thüroff JW; Rennie PS; Gleave ME
Urologe A; 2008 Sep; 47(9):1145-51. PubMed ID: 18670747
[TBL] [Abstract][Full Text] [Related]
5. Highly efficient gene delivery for bladder cancers by intravesically administered replication-competent retroviral vectors.
Kikuchi E; Menendez S; Ozu C; Ohori M; Cordon-Cardo C; Logg CR; Kasahara N; Bochner BH
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4511-8. PubMed ID: 17671137
[TBL] [Abstract][Full Text] [Related]
6. VSV-G pseudotyped, MuLV-based, semi-replication-competent retrovirus for cancer treatment.
Qiao J; Moreno J; Sanchez-Perez L; Kottke T; Thompson J; Caruso M; Diaz RM; Vile R
Gene Ther; 2006 Oct; 13(20):1457-70. PubMed ID: 16724095
[TBL] [Abstract][Full Text] [Related]
7. Down-regulation of type I interferon receptor sensitizes bladder cancer cells to vesicular stomatitis virus-induced cell death.
Zhang KX; Matsui Y; Hadaschik BA; Lee C; Jia W; Bell JC; Fazli L; So AI; Rennie PS
Int J Cancer; 2010 Aug; 127(4):830-8. PubMed ID: 19957332
[TBL] [Abstract][Full Text] [Related]
8. Sensitivity of prostate tumors to wild type and M protein mutant vesicular stomatitis viruses.
Ahmed M; Cramer SD; Lyles DS
Virology; 2004 Dec; 330(1):34-49. PubMed ID: 15527832
[TBL] [Abstract][Full Text] [Related]
9. Interleukin-12 expression enhances vesicular stomatitis virus oncolytic therapy in murine squamous cell carcinoma.
Shin EJ; Wanna GB; Choi B; Aguila D; Ebert O; Genden EM; Woo SL
Laryngoscope; 2007 Feb; 117(2):210-4. PubMed ID: 17204993
[TBL] [Abstract][Full Text] [Related]
10. Systemic therapy of experimental breast cancer metastases by mutant vesicular stomatitis virus in immune-competent mice.
Ebert O; Harbaran S; Shinozaki K; Woo SL
Cancer Gene Ther; 2005 Apr; 12(4):350-8. PubMed ID: 15565179
[TBL] [Abstract][Full Text] [Related]
11. Effects of intravenously administered recombinant vesicular stomatitis virus (VSV(deltaM51)) on multifocal and invasive gliomas.
Lun X; Senger DL; Alain T; Oprea A; Parato K; Stojdl D; Lichty B; Power A; Johnston RN; Hamilton M; Parney I; Bell JC; Forsyth PA
J Natl Cancer Inst; 2006 Nov; 98(21):1546-57. PubMed ID: 17077357
[TBL] [Abstract][Full Text] [Related]
12. Conditionally replicating adenovirus-mediated gene therapy in bladder cancer: an orthotopic in vivo model.
Melquist JJ; Kacka M; Li Y; Malaeb BS; Elmore J; Baseman AG; Hsieh JT; Koeneman KS
Urol Oncol; 2006; 24(4):362-71. PubMed ID: 16818192
[TBL] [Abstract][Full Text] [Related]
13. An improved intravesical model using human bladder cancer cell lines to optimize gene and other therapies.
Watanabe T; Shinohara N; Sazawa A; Harabayashi T; Ogiso Y; Koyanagi T; Takiguchi M; Hashimoto A; Kuzumaki N; Yamashita M; Tanaka M; Grossman HB; Benedict WF
Cancer Gene Ther; 2000 Dec; 7(12):1575-80. PubMed ID: 11228536
[TBL] [Abstract][Full Text] [Related]
14. Paclitaxel and cisplatin as intravesical agents against non-muscle-invasive bladder cancer.
Hadaschik BA; ter Borg MG; Jackson J; Sowery RD; So AI; Burt HM; Gleave ME
BJU Int; 2008 Jun; 101(11):1347-55. PubMed ID: 18384637
[TBL] [Abstract][Full Text] [Related]
15. Oncolytic vesicular stomatitis virus for treatment of orthotopic hepatocellular carcinoma in immune-competent rats.
Ebert O; Shinozaki K; Huang TG; Savontaus MJ; García-Sastre A; Woo SL
Cancer Res; 2003 Jul; 63(13):3605-11. PubMed ID: 12839948
[TBL] [Abstract][Full Text] [Related]
16. Comparison of viral vectors: gene transfer efficiency and tissue specificity in a bladder cancer model.
Siemens DR; Crist S; Austin JC; Tartaglia J; Ratliff T
J Urol; 2003 Sep; 170(3):979-84. PubMed ID: 12913754
[TBL] [Abstract][Full Text] [Related]
17. In vivo evaluation of mucoadhesive nanoparticulate docetaxel for intravesical treatment of non-muscle-invasive bladder cancer.
Mugabe C; Matsui Y; So AI; Gleave ME; Baker JH; Minchinton AI; Manisali I; Liggins R; Brooks DE; Burt HM
Clin Cancer Res; 2011 May; 17(9):2788-98. PubMed ID: 21357680
[TBL] [Abstract][Full Text] [Related]
18. Nonviral cytokine gene therapy on an orthotopic bladder cancer model.
Wu Q; Mahendran R; Esuvaranathan K
Clin Cancer Res; 2003 Oct; 9(12):4522-8. PubMed ID: 14555526
[TBL] [Abstract][Full Text] [Related]
19. Combined VSV oncolytic virus and chemotherapy for squamous cell carcinoma.
Sung CK; Choi B; Wanna G; Genden EM; Woo SL; Shin EJ
Laryngoscope; 2008 Feb; 118(2):237-42. PubMed ID: 18043494
[TBL] [Abstract][Full Text] [Related]
20. In vitro and in vivo effects of CpG-Oligodeoxynucleotides (CpG-ODN) on murine transitional cell carcinoma and on the native murine urinary bladder wall.
Olbert PJ; Schrader AJ; Simon C; Dalpke A; Barth P; Hofmann R; Hegele A
Anticancer Res; 2009 Jun; 29(6):2067-76. PubMed ID: 19528466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]